Ideagen PLC Exercise of Options and Issue of Shares (9294Q)
25 February 2019 - 7:00PM
UK Regulatory
TIDMIDEA
RNS Number : 9294Q
Ideagen PLC
25 February 2019
("Ideagen," "the Company" or the "Group")
Exercise of Options, Issue of Shares and Total Voting Rights
Ideagen PLC (AIM: IDEA), a leading supplier of Information
Management Software to highly regulated industries, announces that
it has allotted a total of 360,612 new ordinary shares of 1 penny
each in the capital of the Company ("Ordinary Shares") following
the exercise of 355,000 options by several employees and the
purchase of a further 5,612 partnership shares by employees through
the Company's Share Incentive Plan.
Application has been made to the London Stock Exchange for the
360,612 new Ordinary Shares to be admitted to trading on AIM
("Admission") and it is expected that Admission will become
effective and trading will commence at 8.00 a.m. on 1 March
2019.
On Admission, the total number of Ordinary Shares in issue will
be 219,773,247 and the total number of voting rights will therefore
be 219,773,247. This figure may be used by shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the share capital of the Company under the FCA's
Disclosure and Transparency Rules.
Enquiries:
Ideagen plc 01629 699100
David Hornsby, Executive Chairman
Ben Dorks, Chief Executive
Graeme Spenceley, Finance Director
finnCap Limited 020 7220 0500
Henrik Persson/James Thompson
(Nomad)
Alice Lane (ECM)
Canaccord Genuity 020 7523 8000
Simon Bridges
Ben Griffiths
Jack Haynes
About Ideagen plc
Ideagen is a UK-headquartered, global technology company quoted
on the London Stock Exchange AIM market (Ticker: IDEA.L).
The Group provides IRM software and services to organisations
operating within highly regulated industries such as aviation,
banking and finance and life science, with its main operational
premises spread throughout the UK, EU, US, Middle East and SE
Asia.
With an excellent portfolio of software products including
Q-Pulse, Coruson, Pentana Audit and PleaseReview, Ideagen helps its
clients reduce costs, improve operational efficiency, strengthen
compliance and oversight and anticipate and manage every detail of
risk.
Currently, more than 4,700 organisations use Ideagen's products
including seven of the top 10 UK accounting firms, all of the top
aerospace and defence companies and 75% of the world's leading
pharmaceutical firms.
Ideagen's diverse and varied customer base includes many
well-known, global brands such as British Airways, Aggreko, BAE,
Ryanair, US Navy, KLM, BBVA, Bank of New York, Commerzbank,
Meggitt, Heineken, Johnson Matthey, Haeco Group and European
Central Bank. As well as this, Ideagen counts 180 hospitals across
the UK and US amongst its client base.
For further information please visit www.ideagen.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TVRUURWRKBAUUAR
(END) Dow Jones Newswires
February 25, 2019 03:00 ET (08:00 GMT)
Ideagen (LSE:IDEA)
Historical Stock Chart
From Apr 2024 to May 2024
Ideagen (LSE:IDEA)
Historical Stock Chart
From May 2023 to May 2024